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ORIGINAL ARTICLES 
Selective incorporation of 
iododeoxyuridine into DNA of hepatic 
metastases versus normal human liver 
Fourteen patients received 5-iodo-2'-deoxyuridine (IdUrd) before surgery for placement of a hepatic 
arterial catheter. Biopsy specimens were obtained at the time of surgery and incorporation of IdUrd into 
deoxyribonucleic acid (DNA) in tumor and normal hepatic tissue was measured by HPLC and used as 
an index of drug selectivity. Over a 3-day intravenous infusion of IdUrd at 1000 mg/ m2/ day, substitution 
for thymidine in tumor DNA averaged 3.1%. Normal hepatic DNA contained <1% substitution by IdUrd. 
Arterial delivery of IdUrd increased levels in DNA, whereas modulation with fluorodeoxyuridine produced 
mixed results. In six patients, flow cytometric analysis showed that the tumor contained a median of 32% 
of tumor cells that had incorporated IdUrd in 3 days, corresponding to a potential doubling time of only 
10 days. Thymidylate synthetase activity in tumors was 20-fold greater than in normal liver tissue, whereas 
thymidine kinase activity was twofold greater in tumors. These pharmacologic studies encourage further 
clinical trials of IdUrd as a cytotoxic agent or radiosensitizer. (QIN PHARmAcor, THER 1988;44:369-75.) 
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Selectivity is the cornerstone of successful cytotoxic 
therapy of cancer. A major drawback to clinically eval- 
uating the selective impact of various therapeutic ma- 
neuvers is an inability to directly examine the target 
tissue, namely, the tumor. Most tumors are inaccessible 
to sampling, except through a major surgical interven- 
tion. Some tumors can be reached by needle biopsy, 
but the amount of tissue obtained is small and may not 
represent the majority of the tumor. 
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Because it is ethically difficult to justify performing 
surgical procedures primarily for purposes of research, 
an alternative approach is to structure research around 
surgical interventions that are already planned and jus- 
tified for other purposes. Biopsy samples obtained at 
the time of scheduled surgery can be used for research 
purposes. These examinations can be made much more 
enlightening if the patient has received some type of 
antitumor treatment before surgery. A clear demon- 
stration of the safety of any presurgical treatment is 
required, especially in light of any interference with 
the scheduled surgery, coagulation, or the wound heal- 
ing process. 
We have undertaken a clinical evaluation of the 
use of intrahepatic arterial infusion of 5-iodo-2'- 
deoxyuridine (IdUrd) in patients with hepatic metas- 
tases from colorectal carcinoma.' All patients required 
laparotomy for placement of a semipermanent catheter 
in the hepatic artery. This surgical requirement provided 
a unique opportunity to obtain biopsy specimens of the 
target tumor and surrounding normal tissue. To maxi- 
mize the information obtained from these specimens, 
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all patients received a 3-day infusion of IdUrd before 
surgery. The effect of various maneuvers that might 
enhance selectivity (changes in dose rate, route of de- 
livery, biochemical modulation) could be readily ex- 
amined with this model system. 
IdUrd is a competitive analog of thymidine (dThd). 
Its cytotoxic activity and radiosensitizing properties 
have been demonstrated both in vitro' and in vivo.'" 
IdUrd was chosen for our study because this drug has 
never been adequately evaluated in clinical trials and 
because its high total body clearance' was a favorable 
property for intraarterial use.' Its mechanism of action 
is thought to be related to incorporation into deoxyri- 
bonucleic acid (DNA), which is readily measurable in 
tissue samples.'" Hepatic metastases were considered 
to be an ideal setting, because a dThd analog could 
maximally exploit differences between dividing tumor 
cells and nondividing liver cells. 
In this study, incorporation of IdUrd into the DNA 
of normal hepatic tissue and tumor tissue was used as 
an index of drug selectivity. DNA levels were deter- 
mined by enzymatic degradation and HPLC measure- 
ment of nucleosides. The fraction of tumor cells that 
divided during the 3-day infusion was determined by 
flow cytometric analysis. A comparative pharmacoki- 
netic study of intravenous vs. intraarterial delivery of 
IdUrd is presented, as well as the impact of 5-fluoro- 
2'-deoxyuridine (FdUrd) on IdUrd incorporation into 
DNA. Furthermore, we estimated the hepatic extraction 
for IdUrd and measured the patterns of two key enzymes 
(thymidylate synthetase and thymidine kinase) in nor- 
mal and tumor tissue. 
MATERIAL AND METHODS 
Clinical. Patients with histologically confirmed, un- 
resectable tumors located in the liver (metastases from 
primary colorectal carcinoma) were eligible for study. 
All patients gave informed consent to participate and 
the study was approved by the Institutional Clinical 
Research Committee. 
IdUrd (NSC 39661) for infusion was supplied by the 
National Cancer Institute. FdUrd was obtained from 
commercial suppliers. When coadministered, the two 
drugs were mixed together and infused simultaneously. 
Patients were admitted before surgery and an IMED 
Corp. infusion pump (San Diego, Calif.) was used to 
deliver a 3-day continuous infusion of IdUrd or FdUrd 
plus IdUrd. The drug solution was infused through ei- 
ther a peripheral vein or a flexible silicone rubber cath- 
eter that had been originally placed into the hepatic 
artery for purposes of percutaneous diagnostic angi- 
ography. 
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The infusion rates (in milligrams per square meter 
per day) for IdUrd or IdUrd plus FdUrd were approx- 
imately the maximally tolerated values for a 14-day 
infusion period, based on our experience." Because the 
infusion period for this study was limited to 3 days, it 
was expected that there would be no toxicity produced 
at these dosages. 
At the time of laparotomy for placement of the 
semipermanent catheter in the hepatic artery, biopsy 
specimens of tumor and normal tissue were taken for 
pharmacologic studies. Two weeks after surgery, pa- 
tients began the intraarterial therapeutic portion of the 
study. The clinical results (toxicity and response) of the 
treatment portion of this study will be reported sepa- 
rately.' 
Enzyme studies. Protein concentrations of the en- 
zyme extract were determined by the method of Brad- 
ford:2 The Biorad assay kit (Richmond, Calif.) was 
used with bovine serum albumin standards. 
The thymidylate synthetase (TS; EC 2.1.1.45) activ- 
ity was determined by the tritium-release method of 
Armstrong and Diasio.' After addition of methylene 
tetrahydrofolate, the reaction was initiated with 15-411- 
deoxyuridine monophosphate (2 Ci/ mmol; Moravek 
Biochemicals, Brea, Calif.) at a final concentration of 
20 limol/ L. The mixture was incubated at 37° C for 
40, 80, and 120 minutes. An aliquot of each sample 
was mixed with charcoal (Norit-A; Baker, Phillipsburg, 
N.J.), dextran, and bovine serum albumin and centri- 
fuged for 5 minutes (Eppendorf centrifuge model 5414; 
Brinkman Instruments Inc., Westbury, N.Y.). The su- 
pernatant was transferred to a second tube, again mixed 
with the charcoal solution, and centrifuged for another 
5 minutes. The supernatant was transferred to a vial, 
scintillation fluid was added, and the sample was 
counted (model 2000CA liquid scintillation analyzer; 
Packard Instruments Company, Sterling, Va.). 
The thymidine kinase (TK; EC 2.7.1.21) activity was 
determined according to Taylor et al.' The supernatant 
from the homogenate was further diluted 1:5, because 
excess enzyme appeared to be inhibitory.' After ad- 
dition of adenosine triphosphate and MgC12, the reac- 
tion was initiated with [methyl-31ThdThd (1 Ci/ mmol; 
Moravek Biochemicals) at a final concentration of 50 
limol/ L. After 10, 20, and 30 minutes of incubation at 
37° C, 50 pi was spotted onto ion exchange paper (2.3 
cm DE81 disk; Whatman, Maidstone, U.K.). The disks 
were washed three times in ammonium formate, trans- 
ferred to 95% ethanol, and dried on a hot plate. The 
disks were placed in vials and soaked in 1.5N 
NaC1/ 0.5N HC1 before liquid scintillation counting. 
Laboratory studies. Two blood samples were drawn 
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during the presurgical infusion and two were drawn 
during subsequent treatment cycles. Blood was col- 
lected in Vacutainer tubes (Becton Dickinson, Ruth- 
erford, N.J.) and immediately placed on ice. After 
centrifugation, plasma was collected and stored at 
20° C until analysis by previously reported HPLC 
methods.' 
Biopsies obtained at the time of placement of the 
semipermanent intraarterial catheter were immediately 
placed on ice. Portions were used for routine pathologic 
examination and flow cytometric analysis. A tissue 
homogenate for DNA incorporation and enzyme stud- 
ies was prepared on ice by diluting the remaining 
minced tissue with four volumes of ice-cold homoge- 
nization buffer (Tris-HC1, 200 mmol/L, pH 7.4; 
2-mercaptoethanol, 200 mmol/L; NaF, 100 mmol/L; 
and cytidylate, 15 mmol/L). The tissue was homoge- 
nized mechanically and sonicated with five 10-second 
bursts at 50 W (Model W-225; Ultrasonics, Inc., Far- 
mingdale, N.Y.). One hundred microliters of homog- 
enate was digested for determination of IdUrd incor- 
poration into DNA." Nucleic acids in the tissue ho- 
mogenate were precipitated by trichloroacetic acid. 
After hydrolysis of ribonucleic acid (RNA) with sodium 
hydroxide, the acid-soluble ribonucleotides were dis- 
carded. DNA was enzymatically digested to the nu- 
cleoside level. Aliquots of the digest were analyzed by 
HPLC. The nucleosides were detected simultaneously 
at 254 nm and at 300 nm. After a 30-minute spin 
(25000 x g, Sorvall RC5; Dupont Instruments, Wil- 
mington, Del.) of the remaining homogenate, the su- 
pernatant was used for measurement of protein content 
and enzymatic activity. The pellet could be used for a 
duplicate determination of IdUrd incorporation into 
DNA. 
Flow cytometry. A single-cell suspension was pre- 
pared by mincing tissue through an 88 p.m gauze and 
washing with phosphate-buffered saline solution. The 
pellet was resuspended in the buffer and three parts of 
95% ethanol was added. This suspension was stored at 
20° C until analysis, usually within 1 week. At the 
time of analysis, the suspension was centrifuged and 
the pellet was resuspended in 2 ml phosphate-buffered 
saline solution to which 2 ml 4N HC1 was added. After 
30 minutes at room temperature, the cells were washed 
with sodium borate (0.1 mol/L, pH 8.5). One million 
cells were resuspended in 50 pL1 phosphate-buffered 
saline solution containing 0.5% Tween 20 (Sigma 
Chemical, St. Louis, Mo.) to which 20 t.1.1 of mono- 
clonal antibody solution was added (Anti-BrdU, fluo- 
rescein conjugate; Becton Dickinson Immunocytometry 
Systems, Mountain View, Calif.). After 30 minutes at 
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Table I. Comparison of intravenous vs. 
intraarterial delivery of a 3-day infusion of 
1000 mg IdUrd/ m2/ day given before biopsy as 
determined by HPLC 
iv, intravenous; ia, intraarterial. 
*No sample obtained. 
t Perfused right lobe only. 
room temperature, the suspension was washed in 
phosphate-buffered saline solution /Tween 20 and re- 
suspended in 100 ill propidium iodide (5 I_Lg / ml in 
phosphate-buffered saline solution; Sigma). 
Four-parameter flow cytometric analysis was per- 
formed on a FACS 440 flow cytometer (Becton Dick- 
inson Immunocytometry Systems) equipped with a 
5 W argon laser (Model 164; Spectraphysics, Piscata- 
way, N.J.) operating at 488 nm and using 200 mW. 
Green fluorescence from the fluorescein isothiocya- 
nate antibodylabeled cells was collected through a 
DF535 /15 bandpass filter (Omega Optical, Brattleboro, 
Vt.) and recorded as a measure of the amount of incor- 
poration of IdUrd. Red fluorescence (DNA content) as 
well as forward and perpendicular light scatter was also 
recorded. In each sample, 20,000 cells were counted 
and histograms of the distribution of IdUrd in each cell 
were obtained. The mean values were expressed in ar- 
bitrary fluorescence units per cell (FU/ cell). 
RESULTS 
Fourteen patients entered this study; 12 were male 
and 2 were female. Median age was 58 years (range 
44 to 68 years). Performance status was 70% to 100% 
(Karnofsky). There was no toxicity observed subse- 
quent to any infusion in this study. 
For five patients who received a 3-day infusion of 
intravenous IdUrd (1000 mg/ m2/ day) before surgery, 
the incorporation of IdUrd into tumor DNA averaged 
3.1%, with a range from 1.7% to 4.5% (Table I, patients 
A to E). In these patients, bilobar hepatic metastases 
were present and tumor biopsy specimens from both 
Patient Route 
IdUrd level in DNA 
Normal 
liver 
Right 
tumor 
Left 
tumor 
A iv * 4.5% 2.5% 
B iv 0.6% 4.1% 4.2% 
C iv 0.8% 3.0% 2.9% 
D iv 0.4% 2.1% 1.7% 
E iv 0.3% 3.1% 2.6% 
F ia 2.4% 3.8% 5.7% 
G ia 0.8% 5.9% * 
Ht ia 1.0% 10.5% 1.6% 
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Table II. Effect of dose rate and coadministration of FdUrd on replacement by IdUrd of dThd in DNA with 
3-day continuous intravenous infusions 
Patient 
Mean ± SD* 
Dose FdUrd 
(mglm'Iday) 
0 
0 
2.4 
2.4 
2.4 
2.4 
2.4 
Dose IdUrd 
(mglm'Iday) 
1000 
400 
450 
450 
450 
450 
450 
*Mean values for the five patients listed in Table I (biopsies of 10 tumors and 4 normal livers). 
No sample obtained. 
the left and right lobes were obtained. In contrast, sam- 
ples of normal liver from these patients had <1% re- 
placement of dThd in DNA. 
When the same dose of IdUrd (1000 mg/ m2/ day 
for 3 days) was delivered via a percutaneous catheter 
placed in the common hepatic artery (Table I, pa- 
tients F and G), incorporation of IdUrd into tumor DNA 
was up to twofold greater than for the intravenous route. 
In patient H, the infusion catheter was selectively 
placed in the right branch of the hepatic artery and tumor 
DNA levels in the right lobe were 10.5%, whereas 
tumor DNA levels in the left lobe were only 1.6% (Table 
I). In this case, delivery of IdUrd to the left lobe re- 
quired an initial passage of drug through the right lobe, 
followed by recirculation to the left lobe via systemic 
circulation. It is noteworthy that the tumor DNA level 
in the left lobe was lower than any values measured 
after intravenous drug delivery (Table I, patients A to 
E). This observation is consistent with presystemic 
elimination of IdUrd during its initial transit through 
the right lobe (first-pass effect). The overall selectivity 
of regional drug delivery in this case was 10.5% vs. 
1.6%, or about sevenfold greater. For two of three pa- 
tients who received intraarterial IdUrd, DNA levels in 
normal liver were For the third patient, a value 
of 2.4% was determined for substitution in DNA of 
normal liver (Table I). 
In one case, the intravenous IdUrd infusion rate was 
400 rather than 1000 mg/m2/day for the 3-day infusion 
period (Table II, patient I). Incorporation of IdUrd into 
tumor DNA was proportionally reduced. For a similar 
dose of IdUrd (450 mg/ m2/ day) a second drug (FdUrd 
at 2.4 mg / m2/ day) was simultaneously infused in five 
patients (J, K, L, N, and P). Compared with patient I, 
Normal 
liver 
0.5 ± 0.1% 
0.3% 
5.6% 
0.5% 
0.4% 
<0.2% 
<0.2% 
IdUrd level in DNA 
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Right Left 
tumor tumor 
3.1% ± 0.3% 
1.3% 1.5% 
4.5% 
5.2% 
0.8% 
1.4% 
1.3% 
the incorporation of IdUrd into tumor DNA in patients 
J and K was three- to fourfold higher (Table II). Com- 
pared with the five patients who received single-agent 
IdUrd at an intravenous dosage of 1000 mg/ m2/ day, 
patients J and K achieved about 50% higher incorpo- 
ration rates. Thus the incorporation for the intravenous 
combination in these two patients was similar to that 
observed for intraarterial IdUrd as a single agent. The 
incorporation for patients L, N, and P was not greater 
than that for patient I, indicating no modulation. The 
average incorporation of IdUrd into tumor DNA for the 
five patients receiving the combination of FdUrd + 
IdUrd (2.6%) was lower than for patients receiving 
IdUrd alone (3.1%). The corresponding levels in DNA 
from normal liver were <1% in four of five cases. 
Patient J had high levels of IdUrd in DNA from both 
tumor (4.5%) and normal liver (5.6%). 
The HPLC results presented in Tables I and II rep- 
resent average values for a tissue sample containing a 
mixture of cells that have no IdUrd incorporated into 
DNA and cells that have incorporated a variable amount 
of IdUrd. Flow cytometric analysis offers the oppor- 
tunity to examine IdUrd incorporation in individual 
cells, based on the fluorescence associated with the 
antibody attached to DNA that contains IdUrd. For all 
patients studied by flow cytometric analysis, the tumor 
contained a substantially higher fraction of cells that 
had incorporated IdUrd as compared with normal liver 
(Table III). 
For the 3-day intravenous infusion data, if one third 
of the tumor cells are labeled and the average dThd 
substitution is 3.1% (Tables I and II), then 10% is the 
average substitution for those tumor cells that contain 
IdUrd ( Fig. 1). For the patient who received selective 
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Table III. Flow cytometric analysis results: 
Fraction of cells that contain IdUrd 
Patient Normal liver Right tumor Left tumor 
*No intact cells in specimen. 
arterial catheterization (Table I, patient H), overall tu- 
mor substitution was 10.5%, so the average substitution 
in those tumor cells that actually contain IdUrd would 
be 32%. 
Enzyme activities for TK and TS (Table IV) were 
measured on the same samples used for DNA analysis. 
TK activity in tumor samples tended to be higher than 
in normal liver samples, but the differences were not 
dramatic. TS activity in tumors was more impressively 
elevated, 10- to 35-fold higher than in normal liver. 
The presurgical infusion of IdUrd could have inhibited 
both enzymes. The dose rate and period of infusion 
were all standardized for the four patients listed in Table 
IV. However, the length of time between the end of 
infusion and sample acquisition could not be carefully 
controlled and ranged from 2 to 6 hours. 
Hepatic extraction of IdUrd can be calculated from 
the steady-state plasma levels for six patients who re- 
ceived separate intraarterial and intravenous infusions. 
The intravenous infusion rate was slightly lower 
than the intraarterial infusion rate (1000 vs. 1333 
mg / m2/ day), so a correction was made for this differ- 
ence. As shown in Table V, the corrected extraction 
values ranged from 29% to 72% (median 70%). 
DISCUSSION 
The results from this pharmacologic study indicate 
that IdUrd possesses several characteristics that would 
be expected to promote selective killing or radiosen- 
sitization of tumor cells. First, for intravenous delivery 
it was shown that tumor cells preferentially incorporate 
IdUrd compared with normal liver cells. Second, when 
the intraarterial route was used, there was additional 
selectivity for target cells. Tumor incorporation of 
IdUrd was higher, and first-pass hepatic extraction low- 
ered systemic tissue exposure. Third, biochemical mod- 
ulation with FdUrd or other drugs may provide some 
increased incorporation of IdUrd into tumor DNA. 
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INCORPORATION 
HOMOGENATE =3% IdUrd INCORPORATION 
Fig. 1. Diagram of IdUrd distribution within hepatic tumor 
after 3 days of intravenous delivery at 1000 mg/1112/day. 
Overall average of 3% substitution composed of two sub- 
populations: two thirds of cells have no IdUrd in DNA, and 
one third of cells have 10% of dThd in DNA replaced by 
IdUrd. 
However, interpatient variability indicates that the par- 
ticular combination used in this study was not practi- 
cal. In fact, for some patients, the combination of 
FdUrd + IdUrd produced lower levels of IdUrd in tu- 
mor DNA than was achieved with single-agent IdUrd. 
Even a hint of tumor selectivity may be worth pursuing, 
because our previous study of DNA from normal gran- 
ulocytes showed that FdUrd did not alter IdUrd levels." 
Flow cytometric analysis provided additional insight 
regarding both tumor cell kinetics and interpretation of 
HPLC results. Substantially more tumor cells than liver 
cells were labeled with IdUrd during the 3-day infusion 
period. In general, this result was expected, based on 
our rationale for selectively treating the cell population 
that was turning over more rapidly. However, the me- 
dian value of 32% labeled tumor cells was perhaps 
higher than anticipated. This fraction corresponds to a 
potential tumor doubling time of 10 days. Because the 
net growth of these tumors is considerably slower, it 
would appear that substantial tumor cell death and sub- 
sequent necrosis is occurring.' 
The optimal time for tumor exposure to drugs, es- 
10% IdUrd 
INCORPORATION 
4% 32% 45% 
9% 16% 
4% 38% 48% 
14% 25% 
2% 71% 
5% 
Median 5% 32% 
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Table IV. Comparison of enzyme activities in normal liver and tumors after 3-day continuous intravenous 
infusion of IdUrd at 1000 mg/ rri2/ day before biopsy 
*No sample obtained. 
Table V. Hepatic extraction* of IdUrd with 
intraarterial (1333 mg / m2/ day) and intravenous 
(1000 mg/ m2/ day) infusions 
Plasma IdUrd (i.unol) 
Patient Intravenous Intraarterial Extraction 
*Extraction is calculated from the difference in steady-state plasma levels, 
corrected for the change in infusion rates. 
pecially cell cyclespecific agents, is closely related to 
their potential doubling time. Based on this rapid turn- 
over time for metastatic tumors in the liver, treatment 
protocols that provide 14-day drug exposure''''"8 would 
be favored over 1- to 5-day infusion periods. 
Due to the difficulties of using flow cytometric anal- 
ysis to quantitate IdUrd incorporation into DNA' 
(Speth et al., unpublished data), only qualitative data 
were obtained by these methods. However, based on 
both the flow cytometric and HPLC results, we have 
inferred that 3 days of intravenous drug delivery pro- 
duced an average IdUrd substitution for dThd of 10% 
(in those tumor cells that contain IdUrd). Because the 
actual exposure durations during treatment are 10 to 14 
days, additional tumor cells will incorporate IdUrd and 
there may also be some increased incorporation in cells 
already containing IdUrd. Based on a variety of studies 
in vitro and in vivo,' at least a doubling of radiation 
effectiveness would be expected at this level of replace- 
ment. For selective arterial delivery, we inferred DNA 
substitution levels >30% in tumor cells containing 
IdUrd, which would suggest radiation enhancement of 
at least fourfold. 
It should be recognized that not all cells that contain 
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IdUrd have entered the S-phase or divided. Some cells 
may have incorporated IdUrd during conservative or 
repair DNA synthesis. If the mechanism of action of 
IdUrd is dependent only on incorporation into DNA, 
the details of the DNA synthetic process are not rele- 
vant. However, it is possible that some of the cytotoxic 
effects of IdUrd are caused by interruption with specific 
steps in DNA synthesis. These details are beyond the 
scope of the current studies. 
Historically, colorectal cancer is considered to have 
de novo resistance to chemotherapy. A variety of mech- 
anisms could be responsible for this pattern of resis- 
tance. For FdUrd and IdUrd, deletion of TK has been 
suggested as one resistance phenotype and is readily 
demonstrable in cell culture studies.' The results of 
these studies (both direct TK assays and IdUrd in DNA) 
strongly reject TK deletion as a source of clinical re- 
sistance de novo. Acquired resistance via TK deletion 
is not addressed by the present work. 
In addition to considerations regarding optimal ex- 
posure time, there is also a need to define the most 
appropriate infusion rate or exposure concentration. In 
general, the highest tolerable infusion rate is desirable, 
but a lower infusion rate for a longer period of time 
may have some advantages. The utility of increasing 
the infusion period may be limited by saturation of drug 
activation processes. The most direct approach would 
be to examine incorporation into DNA vs. the infusion 
rate. The present study did not have adequate numbers 
of patients to pursue this parameter, but does demon- 
strate the feasibility of such an approach. 
Our prior attempts at pharmacologic studies with tu- 
mor biopsy specimens obtained through serendipitous 
events have never been satisfactory. The results of this 
study demonstrate that it is possible to organize the 
process of tissue acquisition to maximize pharmaco- 
logic knowledge. In addition to pharmacologic end 
points, it should be possible to determine some rela- 
tionship for individual patients between studies of the 
biopsy results and treatment outcome when there is a 
Patient 
TK (pmoll minl mg protein) TS (pmoll mini mg protein) 
Normal Right tumor Left tumor Normal Right tumor Left tumor 
A 
B 
C 
D 
* 
62 
15 
37 
82 
83 
190 
29 
190 
160 
92 
38 
0.20 
0.24 
0.12 
6.5 
7.0 
2.5 
1.2 
3.9 
6.6 
4.3 
1.1 
A 3.7 1.5 70% 
3.0 1.1 72% 
4.0 1.6 70% 
2.5 1.4 58% 
3.0 1.1 72% 
2.0 1.9 29% 
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close matching of infusion conditions before and after 
surgery. 
The connection between presurgical and postsurgical 
treatments is not mandatory, and is not always desir- 
able. It may be more logical to perform pilot studies of 
presurgical infusions before making a commitment to 
use any therapeutic approach for the treatment of spe- 
cific tumor types. Several combinations of treatment 
parameters might be attempted before a suitable set of 
therapeutic conditions can be chosen. The results from 
this study have reaffirmed the selection of 14-day in- 
fusion periods for this tumor type and have also dem- 
onstrated that more work remains before it is reasonable 
to proceed with a therapeutic trial of FdUrd + IdUrd. 
We acknowledge helpful discussions regarding this project 
with Dr. Paul H. Fischer at the University of Wisconsin and 
continuing encouragement from Drs. Eli Glatstein and Gisele 
Sarosy of the National Cancer Institute. Dr. James Cupp of 
the National Cancer Institute assisted with the flow cytometric 
analyses. 
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